Skip to main content

Dry Eye Disease Market will generate new growth opportunities 2023-2028

 


Dry eye happens when your eyes don’t make enough tears to stay wet, or when your tears don’t work correctly. This can make your eyes feel uncomfortable, and in some cases it can also cause vision problems. Dry eye disease (DED) is the condition that occurs when tears are not able to provide adequate lubrication to eyes. DED is a multifactorial disease of the ocular surface with loss of homeostasis of the tear film and ocular symptoms. Over-the-counter (OTC) eye drops, such as artificial tears, and prescription eye drops, are effective treatments for dry eye.

Market Dynamics:

Rising incidence of dry eye disease worldwide, rise in demand for safe and effective treatment, rise in focus on the development of novel therapeutics, growing geriatric population, emergence of novel diagnostic tools, and technological advancements are major factors expected to propel the growth of the global dry eye disease market.

Global Dry Eye Disease Market: Regional Insights

Based on geography, the global dry eye disease market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Labels:

Comments

Post a Comment

Popular posts from this blog

The Global Pressure Bandages Market Is Witnessing High Growth Owing To the Increasing Incidence of Surgical Processes in the World

  Market Overview: During a medical emergency, a pressure bandage is used to apply pressure to an area of the body to control bleeding and swelling. There are a variety of types of pressure bandages that can be used for different purposes. The bandage is made up of several parts, including an air bladder, a pad, a closure bar, and an applicator. A pressure bandage can be applied to wounds at any location on the body. This type of dressing is useful in treating various conditions, including gunshot wounds. It can also be used for a temporary holding of a hernia. The bandage is usually vacuum-sealed, so it's easier to carry. Competitive Landscape: Major players operating in the global pressure bandages market include ConvaTec Group PLC., Cardinal Health, 3M, B. Braun Melsungen AG, Lohmann & Rauscher GmbH & Co. KG, Mölnlycke Health Care AB, Smith & Nephew plc., Paul Hartmann AG, and Essity (BSN medical GmbH). Key Market Drivers: Increasing developments by key pla...
Post a Comment
Read more

Increasing Incidences of Infectious Diseases to Augment the Antibacterial Drugs Market Growth

  Antibacterial drugs are widely used to treat and prevent infectious diseases and are categorized into seven major classes, such as β-Lactams, phenicols, macrolides, quinolones, sulfonamides, tetracyclines, and aminoglycosides, based on their molecular structure. Antibacterial drugs destroy or slow down the growth of bacteria. These medications are also used to treat urinary infections caused by S. aureus, E. coli, Streptococcus pyogenes, and other bacterial infections. They include a range of powerful drugs used to treat diseases caused by bacteria. Antibiotics cannot treat viral infections, such as cold, flu, and most coughs. Antibacterial drugs play a major role in advanced healthcare, as they are widely used to treat infectious diseases, such as tuberculosis, malaria, typhoid, leprosy, hepatitis B, HIV/AIDS, and others. Thus, there is an increasing demand for antibacterial drugs worldwide.  
Post a Comment
Read more

Fc Protein and Glycoengineered Antibodies Market Is Booming Worldwide 2023-2028

  Global Fc Protein and Glycoengineered Antibodies Market Drivers Key players in the market are focusing on research and development activities and receiving approvals from regulatory bodies, which are expected to boost the global Fc protein and glycoengineered antibodies market growth over the forecast period. For instance, in 2016, Genentech Inc. received approval from the U.S. Food and drug Administration (U.S. FDA) for Tecentriq (Atezolizumab). It is being used for the treatment of urothelial carcinoma. In March 2019, Tecentriq received its second approval from the U.S. FDA for the treatment of small lung cancer. Furthermore, in November 2017, TG Therapeutics, Inc. began its clinical trial of Ublituximab for the treatment of multiple sclerosis. It is currently in third phase of its clinical trial. Factors such as increasing product approvals and robust pipeline are expected to drive the global fc protein and glycoengineered antibodies market growth.  Increasing preva...
Post a Comment
Read more